Drug Profile
Psoriasis vaccine - Immune Response BioPharma
Alternative Names: IR-502; ZorcellLatest Information Update: 09 Jul 2019
Price :
$50
*
At a glance
- Originator Immune Response Corporation
- Developer Immune Response BioPharma
- Class Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Psoriasis
Highest Development Phases
- No development reported Plaque psoriasis
Most Recent Events
- 09 Jul 2019 No development reported - Phase-II for Plaque psoriasis in USA (IM) (NDR batch #16)
- 08 Mar 2016 Zorcell™ is still in phase IIb trials for Psoriasis in USA (IM, Injection)
- 08 Mar 2016 Zorcell™ is available for licensing (http://www.immuneresponsebiopharma.com/Pages/Partnering.aspx)